婴儿联合接种PHiD-CV与4CMenB疫苗的免疫原性分析
该事后分析基于一项3b期随机对照试验,评估婴儿同时接种PHiD-CV与4CMenB疫苗的免疫原性。婴儿随机分组接受4CMenB+MenC-CRM或仅MenC-CRM,两组均按巴西免疫规划接种PHiD-CV。结果显示两组抗肺炎球菌抗体应答范围相似,提示4CMenB联合接种似乎不影响PHiD-CV的抗体应答。
要点
- 婴儿联合接种4CMenB与PHiD-CV后,抗肺炎球菌抗体应答与单独接种组相似。
- 4CMenB联合接种似乎不影响PHiD-CV的免疫原性。
- 该结论来自3b期随机对照试验的事后分析,需谨慎解读。
核心结论
- 4CMenB联合接种似乎不影响婴儿对PHiD-CV的抗体应答。
研究设计与样本
- 3b期随机对照试验的事后分析(NCT01339923),婴儿随机分为4CMenB+MenC-CRM组或MenC-CRM组。
- 两组均按巴西国家免疫规划接种PHiD-CV(3+1程序:3、5、7、12月龄)。
- 在疫苗接种前、第2剂后1个月、加强前及加强后1个月评估抗体应答。
主要发现
- 两组抗肺炎球菌抗体应答处于相似范围。
临床怎么用
- 临床联合接种4CMenB与PHiD-CV时,无需担心对肺炎球菌疫苗免疫应答的明显干扰。
局限性
- 事后分析,证据等级低于预设主要分析。
- 原文未报告具体样本量、抗体几何平均浓度及置信区间等详细数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No data are currently available on immunogenicity of higher-valent pneumococcal conjugate vaccines when co-administered with a 4-component meningococcal serogroup B vaccine (4CMenB). METHODS: Post-hoc analysis of pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) immunogenicity when co-administered with 4CMenB (2 + 1 schedule) and/or a CRM-conjugated meningococcal serogroup C vaccine (MenC-CRM) in a trial assessing 4CMenB reduced schedules and co-administration with MenC-CRM (NCT01339923). Infants were randomized to receive 4CMenB and MenC-CRM (Group 1) or MenC-CRM (Group 2) at 3, 5, and 12 months (M) of age. Both groups received PHiD-CV (3 + 1 schedule) as part of the Brazilian national immunisation programme at 3 M, 5 M, 7 M, and 12 M of age. Antibody responses were assessed pre-vaccination, 1 M post-dose 2, pre-booster, and 1 M post-booster. RESULTS: Anti-pneumococcal antibody responses were in similar ranges in the two study groups. CONCLUSIONS: 4CMenB co-administration did not seem to impact antibody responses to PHiD-CV in infants.
引用
- Safadi MAP, Martinon-Torres F, Weckx LY, et al. Immunogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered concomitantly with the meningococcal serogroup B (4CMenB) vaccine in infants: A post-hoc analysis in a phase 3b, randomised, controlled trial. Vaccine. 2019. PMID: 31327652. doi:10.1016/j.vaccine.2019.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。